Hospitalization and Survival

In AF/AFL patients with CHF or MI and relatively high risk of sudden death,

TIKOSYN® (dofetilide)—no greater risk of mortality vs placebo1,2

  • At 3 years, mortality rates for TIKOSYN and placebo were similar (45% TIKOSYN, 45% placebo)1,2*

In AF patients with CHF or MI with structural heart disease, 
TIKOSYN demonstrated significant reductions in all-cause and CHF hospitalizations2

Relative risk reduction
in hospitalization for
worsening CHF2

Relative risk reduction
in all-cause hospitalization2

In the EMERALD and SAFIRE-D studies, time to AF/AFL recurrence was significantly longer in the TIKOSYN group1